Connect Biopharma Holdings (CNTB) Long-Term Investments (2022)
Connect Biopharma Holdings (CNTB) posted quarterly Long-Term Investments of $9.2 million for Q4 2022, down 58.55% on a QoQ basis from $22.3 million in Q2 2022.
Connect Biopharma Holdings (CNTB) Long-Term Investments (2022) Analysis & Trends
Connect Biopharma Holdings (CNTB) has reported Long-Term Investments for 1 consecutive years, with $9.2 million the latest figure, recorded in Q4 2022.
- Quarterly Long-Term Investments changed N/A year-over-year to $9.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $9.2 million (changed N/A YoY) and the FY2022 annual result came in at $9.4 million, changed N/A from the prior year.
- Long-Term Investments fell to $9.2 million in Q4 2022 per CNTB's latest filing, from $22.3 million in the prior quarter.
- Over the last five years, Long-Term Investments for CNTB reached as high as $22.3 million in Q2 2022 and fell as low as $9.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 505,194.89 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Connect Biopharma Holdings | 120.44 Mn | 120.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 9.24 Mn |
| Jun 30, 2022 | 22.30 Mn |